1
|
Al Dala Ali M, Longepied G, Nicolet A, Metzler-Guillemain C, Mitchell MJ. Spermatozoa in mice lacking the nucleoporin NUP210L show defects in head shape and motility but not in nuclear compaction or histone replacement. Clin Genet 2024; 105:364-375. [PMID: 38129135 DOI: 10.1111/cge.14468] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/26/2023] [Revised: 11/24/2023] [Accepted: 11/27/2023] [Indexed: 12/23/2023]
Abstract
Biallelic loss-of-function mutation of NUP210L, encoding a testis-specific nucleoporin, has been reported in an infertile man whose spermatozoa show uncondensed heads and histone retention. Mice with a homozygous transgene intronic insertion in Nup210l were infertile but spermatozoa had condensed heads. Expression from this insertion allele is undefined, however, and residual NUP210L production could underlie the milder phenotype. To resolve this issue, we have created Nup210lem1Mjmm , a null allele of Nup210l, in the mouse. Nup210lem1Mjmm homozygotes show uniform mild anomalies of sperm head morphology and decreased motility, but nuclear compaction and histone removal appear unaffected. Thus, our mouse model does not support that NUP210L loss alone blocks spermatid nuclear compaction. Re-analyzing the patient's exome data, we identified a rare, potentially pathogenic, heterozygous variant in nucleoporin gene NUP153 (p.Pro485Leu), and showed that, in mouse and human, NUP210L and NUP153 colocalize at the caudal nuclear pole in elongating spermatids and spermatozoa. Unexpectedly, in round spermatids, NUP210L and NUP153 localisation differs between mouse (nucleoplasm) and human (nuclear periphery). Our data suggest two explanations for the increased phenotypic severity associated with NUP210L loss in human compared to mouse: a genetic variant in human NUP153 (p.Pro485Leu), and inter-species divergence in nuclear pore function in round spermatids.
Collapse
Affiliation(s)
- Maha Al Dala Ali
- Aix Marseille University, Inserm, MMG, Marseille, France
- College of Medicine, Al-Iraqia University, Baghdad, Iraq
| | - Guy Longepied
- Aix Marseille University, Inserm, MMG, Marseille, France
| | - Aurore Nicolet
- Aix Marseille University, Inserm, MMG, Marseille, France
| | - Catherine Metzler-Guillemain
- Aix Marseille University, Inserm, MMG, Marseille, France
- AP-HM, Pôle Femmes-Parents-Enfants, Centre Clinico-biologique AMP-CECOS, Marseille Cedex 5, France
| | | |
Collapse
|
2
|
Lecot-Connan T, Boumerdassi Y, Magnin F, Binart N, Kamenický P, Sonigo C, Beau I. Anti-Müllerian hormone induces autophagy to preserve the primordial follicle pool in mice. FASEB J 2024; 38:e23506. [PMID: 38411466 DOI: 10.1096/fj.202302141r] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/20/2023] [Revised: 01/11/2024] [Accepted: 02/02/2024] [Indexed: 02/28/2024]
Abstract
The reserve pool of primordial follicles (PMFs) is finely regulated by molecules implicated in follicular growth or PMF survival. Anti-Müllerian hormone (AMH), produced by granulosa cells of growing follicles, is known for its inhibitory role in the initiation of PMF growth. We observed in a recent in vivo study that injection of AMH into mice seemed to induce an activation of autophagy. Furthermore, injection of AMH into mice activates the transcription factor FOXO3A which is also known for its implication in autophagy regulation. Many studies highlighted the key role of autophagy in the ovary at different stages of folliculogenesis, particularly in PMF survival. Through an in vitro approach with organotypic cultures of prepubertal mouse ovaries, treated or not with AMH, we aimed to understand the link among AMH, autophagy, and FOXO3A transcription factor. Autophagy and FOXO3A phosphorylation were analyzed by western blot. The expression of genes involved in autophagy was quantified by RT-qPCR. In our in vitro model, we confirmed the decrease in FOXO3A phosphorylation and the induction of autophagy in ovaries incubated with AMH. AMH also induces the expression of genes involved in autophagy. Interestingly, most of these genes are known to be FOXO3A target genes. In conclusion, we have identified a new role for AMH, namely the induction of autophagy, probably through FOXO3A activation. Thus, AMH protects the ovarian reserve not only by inhibiting the growth of PMFs but also by enabling their survival through activation of autophagy.
Collapse
Affiliation(s)
- Tatiana Lecot-Connan
- Université Paris-Saclay, Inserm, Physiologie et Physiopathologie Endocriniennes, Le Kremlin-Bicêtre, France
| | - Yasmine Boumerdassi
- Université Paris-Saclay, Inserm, Physiologie et Physiopathologie Endocriniennes, Le Kremlin-Bicêtre, France
| | - Françoise Magnin
- Université Paris-Saclay, Inserm, Physiologie et Physiopathologie Endocriniennes, Le Kremlin-Bicêtre, France
| | - Nadine Binart
- Université Paris-Saclay, Inserm, Physiologie et Physiopathologie Endocriniennes, Le Kremlin-Bicêtre, France
| | - Peter Kamenický
- Université Paris-Saclay, Inserm, Physiologie et Physiopathologie Endocriniennes, Le Kremlin-Bicêtre, France
- AP-HP, Hôpital Bicêtre, Service d'Endocrinologie et des Maladies de la Reproduction, Centre de Référence des Maladies Rares de l'Hypophyse, Le Kremlin-Bicêtre, France
| | - Charlotte Sonigo
- Université Paris-Saclay, Inserm, Physiologie et Physiopathologie Endocriniennes, Le Kremlin-Bicêtre, France
- AP-HP, Hôpital Antoine Béclère, Service de Médecine de la reproduction et Préservation de la Fertilité, Clamart, France
| | - Isabelle Beau
- Université Paris-Saclay, Inserm, Physiologie et Physiopathologie Endocriniennes, Le Kremlin-Bicêtre, France
| |
Collapse
|
3
|
Ben Moussa O, Parveau L, Aouimeur I, Egaud G, Maurin C, Fraine S, Urbaniak S, Perrache C, He Z, Xxx S, Dorado Cortez O, Poinard S, Mauclair C, Gain P, Thuret G. Femtosecond Laser Cutting of Human Crystalline Lens Capsule and Decellularization for Corneal Endothelial Bioengineering. Bioengineering (Basel) 2024; 11:255. [PMID: 38534529 DOI: 10.3390/bioengineering11030255] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/01/2024] [Revised: 02/28/2024] [Accepted: 03/01/2024] [Indexed: 03/28/2024] Open
Abstract
The bioengineering of corneal endothelial grafts consists of seeding in vitro cultured corneal endothelial cells onto a thin, transparent, biocompatible, and sufficiently robust carrier which can withstand surgical manipulations. This is one of the most realistic alternatives to donor corneas, which are in chronic global shortage. The anterior capsule of the crystalline lens has already been identified as one of the best possible carriers, but its challenging manual preparation has limited its use. In this study, we describe a femtosecond laser cutting process of the anterior capsule of whole lenses in order to obtain capsule discs of 8 mm diameter, similar to conventional endothelial grafts. Circular marks made on the periphery of the disc indicate its orientation. Immersion in water for 3 days is sufficient to completely remove the lens epithelial cells and to enable the seeding of corneal endothelial cells, which remain viable after 27 days of culture. Therefore, this method provides a transparent, decellularized disc ready to form viable tissue engineered endothelial grafts.
Collapse
Affiliation(s)
- Olfa Ben Moussa
- Laboratory Biology, Engineering and Imaging for Ophthalmology, BiiO, Faculty of Medicine, Health Innovation Campus, Jean Monnet University, 10 Rue de la Marandière, 42270 Saint-Priest-en-Jarez, France
| | - Louise Parveau
- Laboratory Biology, Engineering and Imaging for Ophthalmology, BiiO, Faculty of Medicine, Health Innovation Campus, Jean Monnet University, 10 Rue de la Marandière, 42270 Saint-Priest-en-Jarez, France
| | - Inès Aouimeur
- Laboratory Biology, Engineering and Imaging for Ophthalmology, BiiO, Faculty of Medicine, Health Innovation Campus, Jean Monnet University, 10 Rue de la Marandière, 42270 Saint-Priest-en-Jarez, France
| | - Grégory Egaud
- GIE Manutech-USD, 18 Rue Professeur Benoît Lauras, 42000 Saint-Etienne, France
| | - Corantin Maurin
- Laboratory Biology, Engineering and Imaging for Ophthalmology, BiiO, Faculty of Medicine, Health Innovation Campus, Jean Monnet University, 10 Rue de la Marandière, 42270 Saint-Priest-en-Jarez, France
| | - Sofiane Fraine
- Laboratory Biology, Engineering and Imaging for Ophthalmology, BiiO, Faculty of Medicine, Health Innovation Campus, Jean Monnet University, 10 Rue de la Marandière, 42270 Saint-Priest-en-Jarez, France
| | - Sébastien Urbaniak
- Laboratory Biology, Engineering and Imaging for Ophthalmology, BiiO, Faculty of Medicine, Health Innovation Campus, Jean Monnet University, 10 Rue de la Marandière, 42270 Saint-Priest-en-Jarez, France
| | - Chantal Perrache
- Laboratory Biology, Engineering and Imaging for Ophthalmology, BiiO, Faculty of Medicine, Health Innovation Campus, Jean Monnet University, 10 Rue de la Marandière, 42270 Saint-Priest-en-Jarez, France
| | - Zhiguo He
- Laboratory Biology, Engineering and Imaging for Ophthalmology, BiiO, Faculty of Medicine, Health Innovation Campus, Jean Monnet University, 10 Rue de la Marandière, 42270 Saint-Priest-en-Jarez, France
| | - Sedao Xxx
- Laboratoire Hubert Curien, Jean Monnet University, 18 Rue Professeur Benoît Lauras, 42000 Saint-Etienne, France
| | - Oliver Dorado Cortez
- Laboratory Biology, Engineering and Imaging for Ophthalmology, BiiO, Faculty of Medicine, Health Innovation Campus, Jean Monnet University, 10 Rue de la Marandière, 42270 Saint-Priest-en-Jarez, France
- Ophthalmology Department, University Hospital, Avenue Albert Raimond, CEDEX 02, 42055 Saint-Etienne, France
| | - Sylvain Poinard
- Laboratory Biology, Engineering and Imaging for Ophthalmology, BiiO, Faculty of Medicine, Health Innovation Campus, Jean Monnet University, 10 Rue de la Marandière, 42270 Saint-Priest-en-Jarez, France
- Ophthalmology Department, University Hospital, Avenue Albert Raimond, CEDEX 02, 42055 Saint-Etienne, France
| | - Cyril Mauclair
- Laboratoire Hubert Curien, Jean Monnet University, 18 Rue Professeur Benoît Lauras, 42000 Saint-Etienne, France
| | - Philippe Gain
- Laboratory Biology, Engineering and Imaging for Ophthalmology, BiiO, Faculty of Medicine, Health Innovation Campus, Jean Monnet University, 10 Rue de la Marandière, 42270 Saint-Priest-en-Jarez, France
- Ophthalmology Department, University Hospital, Avenue Albert Raimond, CEDEX 02, 42055 Saint-Etienne, France
| | - Gilles Thuret
- Laboratory Biology, Engineering and Imaging for Ophthalmology, BiiO, Faculty of Medicine, Health Innovation Campus, Jean Monnet University, 10 Rue de la Marandière, 42270 Saint-Priest-en-Jarez, France
- Ophthalmology Department, University Hospital, Avenue Albert Raimond, CEDEX 02, 42055 Saint-Etienne, France
| |
Collapse
|
4
|
Sakhi H, Beaumier M, Couchoud C, Prezelin-Reydit M, Radenac J, Lobbedez T, Morin D, Audard V, Chatelet V. Social deprivation and kidney failure due to an undiagnosed nephropathy. Nephrol Dial Transplant 2023; 39:133-140. [PMID: 37580138 DOI: 10.1093/ndt/gfad174] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/11/2023] [Indexed: 08/16/2023] Open
Abstract
BACKGROUND In France, kidney diseases of undetermined origin account for 5%-20% of all causes of end-stage kidney disease. We investigated the impact of social disadvantage on the lack of aetiological diagnosis of nephropathies. METHODS Data from patients who started dialysis in France between 1 January 2017 and 30 June 2018 were extracted from the French Renal Epidemiology and Information Network registry. The social deprivation of each individual was estimated by the European Deprivation Index (EDI) defined by the patient's address. Logistic regression was used to perform mediation analysis to study the potential association between social deprivation and unknown nephropathy. RESULTS Of the 7218 patients included, 1263 (17.5%) had unknown kidney disease. A total of 394 (31.4%) patients in the unknown kidney disease belonged to the most deprived quintile of the EDI [fifth quintile (Q5)], vs 1636 (27.5%) patients in the known kidney disease group. In the multivariate analysis, unknown kidney disease was associated with Q5 (odds ratio 1.40, 95% confidence interval 1.12-1.74, P = .003). Mediation analysis did not identify any variables (e.g. obesity, initiation of dialysis in emergency, number of visits to the general practitioner and nephrologist before initiation of dialysis, date of first nephrology consultation) that mediated the association between social deprivation and nephropathy of unknown origin. CONCLUSIONS Our results show that, compared with nondeprived subjects, individuals experiencing social deprivation have a higher risk of unknown nephropathy at dialysis initiation. However, mediation analysis did not identify any variables that explained the association between social deprivation and nephropathy of unknown origin.
Collapse
Affiliation(s)
- Hamza Sakhi
- Assistance Publique des Hôpitaux de Paris (AP-HP), Department of Nephrology, Dialysis and Transplantation, CHU Necker, Paris, France
| | - Mathilde Beaumier
- Centre Universitaire des maladies rénales, CHU de Caen Normandie, Caen, France
- Unit INSERM 1086 ANTICIPE, centre de lutte contre le cancer François Baclesse, Caen, France
| | - Cécile Couchoud
- REIN Registry, Biomedecine Agency, Saint-Denis-La-Plaine, France
| | - Mathilde Prezelin-Reydit
- Maison du Rein AURAD Aquitaine, Gradignan, France
- Université de Bordeaux, INSERM, CIC1401-EC, Bordeaux, France
| | - Jennifer Radenac
- Filière ORKiD (Orphan Rare Kidney Disease), CHU de Montpellier, Montpellier, France
| | - Thierry Lobbedez
- Centre Universitaire des maladies rénales, CHU de Caen Normandie, Caen, France
- Unit INSERM 1086 ANTICIPE, centre de lutte contre le cancer François Baclesse, Caen, France
| | - Denis Morin
- Filière ORKiD (Orphan Rare Kidney Disease), CHU de Montpellier, Montpellier, France
- Department of Pediatric Nephrology and Endocrinology, CHU de Montpellier, Montpellier, France
| | - Vincent Audard
- Filière ORKiD (Orphan Rare Kidney Disease), CHU de Montpellier, Montpellier, France
- AP-HP, Department of Nephrology and Transplantation, Henri Mondor Hospital University, Centre de Référence Maladie Rare « Syndrome Néphrotique Idiopathique », Fédération Hospitalo-Universitaire « Innovative therapy for immune disorders », Créteil, France
- Université Paris Est Créteil, Institut National de la Santé et de la Recherche Médicale (INSERM) U955, Institut Mondor de Recherche Biomédicale (IMRB), Créteil, France
| | - Valérie Chatelet
- Centre Universitaire des maladies rénales, CHU de Caen Normandie, Caen, France
| |
Collapse
|
5
|
Michon-Colin A, Metzger M, Bankir L, Gauci C, Brunel M, Baron S, Prot-Bertoye C, Stengel B, Thervet E, Haymann JP, Boffa JJ, Vrtovsnik F, Flamant M, Houillier P, Prie D, Courbebaisse M. Fibroblast growth factor 23 but not copeptin is independently associated with kidney failure and mortality in patients with chronic kidney disease. Clin Kidney J 2023; 16:2472-2481. [PMID: 38046034 PMCID: PMC10689138 DOI: 10.1093/ckj/sfad149] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/28/2023] [Indexed: 12/05/2023] Open
Abstract
Background Copeptin and intact fibroblast growth factor 23 (iFGF23) increase early during chronic kidney disease (CKD) and may be predictive of unfavourable outcomes. The aim of this study was to evaluate their respective associations with renal and vital outcomes in CKD patients. Methods We included CKD patients from the NephroTest cohort with concomitant measurements of plasma copeptin and iFGF23 concentrations and isotopic glomerular filtration rate measurement (mGFR). The primary endpoint was a composite outcome including kidney failure (KF) (dialysis initiation, pre-emptive transplantation or a 57% decrease of mGFR, corresponding to doubling of serum creatinine) or death before KF. Hazard ratios (HRs) of the primary endpoint associated with log-transformed copeptin and iFGF23 concentrations were estimated by Cox models. The slope of mGFR over time was analysed using a linear mixed model. Results A total of 329 CKD patients (243 men, mean age 60.3 ± 14.6 years) were included. Among them, 301 with an mGFR >15 ml/min/1.73 m2 were included in survival and mGFR slope analyses. During a median follow-up of 4.61 years (quartile 1-quartile 3: 3.72-6.07), 61 KFs and 32 deaths occurred. Baseline iFGF23 concentrations were associated with the composite outcome after multiple adjustments {HR 2.72 [95% confidence interval (CI) 1.85-3.99]}, whereas copeptin concentrations were not [HR 1.01 (95% CI 0.74-1.39)]. Neither copeptin nor iFGF23 were associated with mGFR slope over time. Conclusion Our study shows for the first time in population of CKD patients an independent association between iFGF23 and unfavourable renal and vital outcomes and shows no such association regarding copeptin, encouraging the integration of iFGF23 measurement into the follow-up of CKD.
Collapse
Affiliation(s)
- Arthur Michon-Colin
- Université Paris Cité, Paris, France
- Explorations Fonctionnelles Rénales – Physiologie, Hôpital Européen Georges-Pompidou, Assistance Publique – Hôpitaux de Paris, Paris, France
- Centre de Référence des Maladies Rénales Héréditaires de l’Enfant et de l’Adulte, Paris, France
- Centre de Référence des Maladies Rares du Calcium et du Phosphate, Paris, France
| | - Marie Metzger
- INSERM UMRS 1018, Equipe d'Epidémiologie Clinique, CESP, Université Paris-Saclay, Villejuif, France
| | - Lise Bankir
- Centre de Recherche des Cordeliers, INSERM, Sorbonne Université, Université Paris Cité, Paris, France
- CNRS, ERL 8228, Laboratory of Kidney Physiology and Tubulopathies, Paris, France
| | - Cédric Gauci
- Explorations Fonctionnelles Rénales – Physiologie, Hôpital Européen Georges-Pompidou, Assistance Publique – Hôpitaux de Paris, Paris, France
- INSERM UMRS 1018, Equipe d'Epidémiologie Clinique, CESP, Université Paris-Saclay, Villejuif, France
| | - Mélanie Brunel
- Université Paris Cité, Paris, France
- Explorations Fonctionnelles Rénales – Physiologie, Hôpital Européen Georges-Pompidou, Assistance Publique – Hôpitaux de Paris, Paris, France
- Centre de Référence des Maladies Rénales Héréditaires de l’Enfant et de l’Adulte, Paris, France
- Centre de Référence des Maladies Rares du Calcium et du Phosphate, Paris, France
| | - Stéphanie Baron
- Université Paris Cité, Paris, France
- Explorations Fonctionnelles Rénales – Physiologie, Hôpital Européen Georges-Pompidou, Assistance Publique – Hôpitaux de Paris, Paris, France
- Centre de Recherche des Cordeliers, INSERM, Sorbonne Université, Université Paris Cité, Paris, France
- Centre de Référence des Maladies Rénales Héréditaires de l’Enfant et de l’Adulte, Paris, France
- Centre de Référence des Maladies Rares du Calcium et du Phosphate, Paris, France
| | - Caroline Prot-Bertoye
- Explorations Fonctionnelles Rénales – Physiologie, Hôpital Européen Georges-Pompidou, Assistance Publique – Hôpitaux de Paris, Paris, France
- Centre de Recherche des Cordeliers, INSERM, Sorbonne Université, Université Paris Cité, Paris, France
- CNRS, ERL 8228, Laboratory of Kidney Physiology and Tubulopathies, Paris, France
- Centre de Référence des Maladies Rénales Héréditaires de l’Enfant et de l’Adulte, Paris, France
- Centre de Référence des Maladies Rares du Calcium et du Phosphate, Paris, France
| | - Bénédicte Stengel
- INSERM UMRS 1018, Equipe d'Epidémiologie Clinique, CESP, Université Paris-Saclay, Villejuif, France
| | - Eric Thervet
- Université Paris Cité, Paris, France
- Néphrologie et Hémodialyse, Hôpital Européen Georges-Pompidou, Assistance Publique – Hôpitaux de Paris, Paris, France
| | - Jean-Philippe Haymann
- Explorations Fonctionnelles Multidisciplinaires, Sorbonne Université Paris, France
- Explorations Fonctionnelles Multidisciplinaires, Hôpital Tenon, Assistance Publique – Hôpitaux de Paris, Paris, France
| | - Jean-Jacques Boffa
- Explorations Fonctionnelles Multidisciplinaires, Sorbonne Université Paris, France
- Néphrologie et Dialyse, Hôpital Tenon, Assistance Publique – Hôpitaux de Paris, Paris, France
| | - François Vrtovsnik
- Université Paris Cité, Paris, France
- Néphrologie, Hôpital Bichat, Assistance Publique – Hôpitaux de Paris, Paris, France
| | - Martin Flamant
- Université Paris Cité, Paris, France
- Explorations Fonctionnelles Multidisciplinaires, Hôpital Bichat, Assistance Publique – Hôpitaux de Paris, Paris, France
| | - Pascal Houillier
- Université Paris Cité, Paris, France
- Explorations Fonctionnelles Rénales – Physiologie, Hôpital Européen Georges-Pompidou, Assistance Publique – Hôpitaux de Paris, Paris, France
- Centre de Recherche des Cordeliers, INSERM, Sorbonne Université, Université Paris Cité, Paris, France
- Centre de Référence des Maladies Rénales Héréditaires de l’Enfant et de l’Adulte, Paris, France
- Centre de Référence des Maladies Rares du Calcium et du Phosphate, Paris, France
| | - Dominique Prie
- Université Paris Cité, Paris, France
- INSERM U1151, Institut Necker Enfants Malades, Paris, France
- Département de Physiologie, Hôpital Necker, Assistance Publique – Hôpitaux de Paris, Paris, France
| | - Marie Courbebaisse
- Université Paris Cité, Paris, France
- Explorations Fonctionnelles Rénales – Physiologie, Hôpital Européen Georges-Pompidou, Assistance Publique – Hôpitaux de Paris, Paris, France
- INSERM U1151, Institut Necker Enfants Malades, Paris, France
- Centre de Référence des Maladies Rénales Héréditaires de l’Enfant et de l’Adulte, Paris, France
- Centre de Référence des Maladies Rares du Calcium et du Phosphate, Paris, France
| |
Collapse
|
6
|
Ba R, Durand A, Mauduit V, Chauveau C, Le Bas-Bernardet S, Salle S, Guérif P, Morin M, Petit C, Douillard V, Rousseau O, Blancho G, Kerleau C, Vince N, Giral M, Gourraud PA, Limou S. KiT-GENIE, the French genetic biobank of kidney transplantation. Eur J Hum Genet 2023; 31:1291-1299. [PMID: 36737541 PMCID: PMC10620190 DOI: 10.1038/s41431-023-01294-z] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/04/2022] [Revised: 12/16/2022] [Accepted: 01/16/2023] [Indexed: 02/05/2023] Open
Abstract
KiT-GENIE is a monocentric DNA biobank set up to consolidate the very rich and homogeneous DIVAT French cohort of kidney donors and recipients (D/R) in order to explore the molecular factors involved in kidney transplantation outcomes. We collected DNA samples for kidney transplantations performed in Nantes, and we leveraged GWAS genotyping data for securing high-quality genetic data with deep SNP and HLA annotations through imputations and for inferring D/R genetic ancestry. Overall, the biobank included 4217 individuals (n = 1945 D + 2,272 R, including 1969 D/R pairs), 7.4 M SNPs and over 200 clinical variables. KiT-GENIE represents an accurate snapshot of kidney transplantation clinical practice in Nantes between 2002 and 2018, with an enrichment in living kidney donors (17%) and recipients with focal segmental glomerulosclerosis (4%). Recipients were predominantly male (63%), of European ancestry (93%), with a mean age of 51yo and 86% experienced their first graft over the study period. D/R pairs were 93% from European ancestry, and 95% pairs exhibited at least one HLA allelic mismatch. The mean follow-up time was 6.7 years with a hindsight up to 25 years. Recipients experienced biopsy-proven rejection and graft loss for 16.6% and 21.3%, respectively. KiT-GENIE constitutes one of the largest kidney transplantation genetic cohorts worldwide to date. It includes homogeneous high-quality clinical and genetic data for donors and recipients, hence offering a unique opportunity to investigate immunogenetic and genetic factors, as well as donor-recipient interactions and mismatches involved in rejection, graft survival, primary disease recurrence and other comorbidities.
Collapse
Affiliation(s)
- Rokhaya Ba
- Nantes Université, Centrale Nantes, CHU Nantes, Inserm, Centre de Recherche Translationnelle en Transplantation et Immunologie, UMR 1064, F-44000, Nantes, France
| | - Axelle Durand
- Nantes Université, Centrale Nantes, CHU Nantes, Inserm, Centre de Recherche Translationnelle en Transplantation et Immunologie, UMR 1064, F-44000, Nantes, France
| | - Vincent Mauduit
- Nantes Université, Centrale Nantes, CHU Nantes, Inserm, Centre de Recherche Translationnelle en Transplantation et Immunologie, UMR 1064, F-44000, Nantes, France
| | - Christine Chauveau
- Nantes Université, Centrale Nantes, CHU Nantes, Inserm, Centre de Recherche Translationnelle en Transplantation et Immunologie, UMR 1064, F-44000, Nantes, France
| | - Stéphanie Le Bas-Bernardet
- Nantes Université, Centrale Nantes, CHU Nantes, Inserm, Centre de Recherche Translationnelle en Transplantation et Immunologie, UMR 1064, F-44000, Nantes, France
| | - Sonia Salle
- Nantes Université, Centrale Nantes, CHU Nantes, Inserm, Centre de Recherche Translationnelle en Transplantation et Immunologie, UMR 1064, F-44000, Nantes, France
| | - Pierrick Guérif
- CHU Nantes, Nantes Université, Service de Néphrologie-Immunologie Clinique, ITUN, F-44000, Nantes, France
| | - Martin Morin
- Nantes Université, Centrale Nantes, CHU Nantes, Inserm, Centre de Recherche Translationnelle en Transplantation et Immunologie, UMR 1064, F-44000, Nantes, France
| | - Clémence Petit
- Nantes Université, Centrale Nantes, CHU Nantes, Inserm, Centre de Recherche Translationnelle en Transplantation et Immunologie, UMR 1064, F-44000, Nantes, France
- CHU Nantes, Nantes Université, Service de Néphrologie-Immunologie Clinique, ITUN, F-44000, Nantes, France
| | - Venceslas Douillard
- Nantes Université, Centrale Nantes, CHU Nantes, Inserm, Centre de Recherche Translationnelle en Transplantation et Immunologie, UMR 1064, F-44000, Nantes, France
| | - Olivia Rousseau
- Nantes Université, Centrale Nantes, CHU Nantes, Inserm, Centre de Recherche Translationnelle en Transplantation et Immunologie, UMR 1064, F-44000, Nantes, France
| | - Gilles Blancho
- Nantes Université, Centrale Nantes, CHU Nantes, Inserm, Centre de Recherche Translationnelle en Transplantation et Immunologie, UMR 1064, F-44000, Nantes, France
- CHU Nantes, Nantes Université, Service de Néphrologie-Immunologie Clinique, ITUN, F-44000, Nantes, France
| | - Clarisse Kerleau
- CHU Nantes, Nantes Université, Service de Néphrologie-Immunologie Clinique, ITUN, F-44000, Nantes, France
| | - Nicolas Vince
- Nantes Université, Centrale Nantes, CHU Nantes, Inserm, Centre de Recherche Translationnelle en Transplantation et Immunologie, UMR 1064, F-44000, Nantes, France
| | - Magali Giral
- Nantes Université, Centrale Nantes, CHU Nantes, Inserm, Centre de Recherche Translationnelle en Transplantation et Immunologie, UMR 1064, F-44000, Nantes, France
- CHU Nantes, Nantes Université, Service de Néphrologie-Immunologie Clinique, ITUN, F-44000, Nantes, France
| | - Pierre-Antoine Gourraud
- Nantes Université, Centrale Nantes, CHU Nantes, Inserm, Centre de Recherche Translationnelle en Transplantation et Immunologie, UMR 1064, F-44000, Nantes, France
| | - Sophie Limou
- Nantes Université, Centrale Nantes, CHU Nantes, Inserm, Centre de Recherche Translationnelle en Transplantation et Immunologie, UMR 1064, F-44000, Nantes, France.
| |
Collapse
|
7
|
Karam A, Delvallée C, Estrada-Cuzcano A, Geoffroy V, Lamouche JB, Leuvrey AS, Nourisson E, Tarabeux J, Stoetzel C, Scheidecker S, Porter LF, Génin E, Redon R, Sandron F, Boland A, Deleuze JF, Le May N, Dollfus H, Muller J. WGS Revealed Novel BBS5 Pathogenic Variants, Missed by WES, Causing Ciliary Structure and Function Defects. Int J Mol Sci 2023; 24:8729. [PMID: 37240074 PMCID: PMC10218572 DOI: 10.3390/ijms24108729] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/31/2023] [Revised: 04/18/2023] [Accepted: 04/24/2023] [Indexed: 05/28/2023] Open
Abstract
Bardet-Biedl syndrome (BBS) is an autosomal recessive ciliopathy that affects multiple organs, leading to retinitis pigmentosa, polydactyly, obesity, renal anomalies, cognitive impairment, and hypogonadism. Until now, biallelic pathogenic variants have been identified in at least 24 genes delineating the genetic heterogeneity of BBS. Among those, BBS5 is a minor contributor to the mutation load and is one of the eight subunits forming the BBSome, a protein complex implied in protein trafficking within the cilia. This study reports on a European BBS5 patient with a severe BBS phenotype. Genetic analysis was performed using multiple next-generation sequencing (NGS) tests (targeted exome, TES and whole exome, WES), and biallelic pathogenic variants could only be identified using whole-genome sequencing (WGS), including a previously missed large deletion of the first exons. Despite the absence of family samples, the biallelic status of the variants was confirmed. The BBS5 protein's impact was confirmed on the patient's cells (presence/absence and size of the cilium) and ciliary function (Sonic Hedgehog pathway). This study highlights the importance of WGS and the challenge of reliable structural variant detection in patients' genetic explorations as well as functional tests to assess a variant's pathogenicity.
Collapse
Affiliation(s)
- Adella Karam
- Laboratoire de Génétique Médicale, UMR_S INSERM U1112, Institut de Génétique Médicale d’Alsace (IGMA), Faculté de Médecine FMTS, Université de Strasbourg, 67000 Strasbourg, France
| | - Clarisse Delvallée
- Laboratoire de Génétique Médicale, UMR_S INSERM U1112, Institut de Génétique Médicale d’Alsace (IGMA), Faculté de Médecine FMTS, Université de Strasbourg, 67000 Strasbourg, France
| | - Alejandro Estrada-Cuzcano
- Laboratoire de Génétique Médicale, UMR_S INSERM U1112, Institut de Génétique Médicale d’Alsace (IGMA), Faculté de Médecine FMTS, Université de Strasbourg, 67000 Strasbourg, France
| | - Véronique Geoffroy
- Laboratoire de Génétique Médicale, UMR_S INSERM U1112, Institut de Génétique Médicale d’Alsace (IGMA), Faculté de Médecine FMTS, Université de Strasbourg, 67000 Strasbourg, France
| | - Jean-Baptiste Lamouche
- Laboratoire de Génétique Médicale, UMR_S INSERM U1112, Institut de Génétique Médicale d’Alsace (IGMA), Faculté de Médecine FMTS, Université de Strasbourg, 67000 Strasbourg, France
| | - Anne-Sophie Leuvrey
- Laboratoires de Diagnostic Génétique, Hôpitaux Universitaires de Strasbourg, 67000 Strasbourg, France (E.N.)
| | - Elsa Nourisson
- Laboratoires de Diagnostic Génétique, Hôpitaux Universitaires de Strasbourg, 67000 Strasbourg, France (E.N.)
| | - Julien Tarabeux
- Laboratoires de Diagnostic Génétique, Hôpitaux Universitaires de Strasbourg, 67000 Strasbourg, France (E.N.)
| | - Corinne Stoetzel
- Laboratoire de Génétique Médicale, UMR_S INSERM U1112, Institut de Génétique Médicale d’Alsace (IGMA), Faculté de Médecine FMTS, Université de Strasbourg, 67000 Strasbourg, France
| | - Sophie Scheidecker
- Laboratoire de Génétique Médicale, UMR_S INSERM U1112, Institut de Génétique Médicale d’Alsace (IGMA), Faculté de Médecine FMTS, Université de Strasbourg, 67000 Strasbourg, France
- Laboratoires de Diagnostic Génétique, Hôpitaux Universitaires de Strasbourg, 67000 Strasbourg, France (E.N.)
| | - Louise Frances Porter
- Laboratoire de Génétique Médicale, UMR_S INSERM U1112, Institut de Génétique Médicale d’Alsace (IGMA), Faculté de Médecine FMTS, Université de Strasbourg, 67000 Strasbourg, France
- Centre de Référence Pour les Affections Rares en Génétique Ophtalmologique (CARGO), Institut de Génétique Médicale d’Alsace (IGMA), Filière SENSGENE, Hôpitaux Universitaires de Strasbourg, 67091 Strasbourg, France
| | - Emmanuelle Génin
- Inserm, Université de Brest, EFS, UMR 1078, GGB, F-29200 Brest, France
| | - Richard Redon
- CHU Nantes, CNRS, INSERM, L’institut du Thorax, Nantes Université, 44000 Nantes, France
| | - Florian Sandron
- CEA, Centre National de Recherche en Génomique Humaine, Université Paris-Saclay, 91057 Evry, France
| | - Anne Boland
- CEA, Centre National de Recherche en Génomique Humaine, Université Paris-Saclay, 91057 Evry, France
| | - Jean-François Deleuze
- CEA, Centre National de Recherche en Génomique Humaine, Université Paris-Saclay, 91057 Evry, France
| | - Nicolas Le May
- Laboratoire de Génétique Médicale, UMR_S INSERM U1112, Institut de Génétique Médicale d’Alsace (IGMA), Faculté de Médecine FMTS, Université de Strasbourg, 67000 Strasbourg, France
| | - Hélène Dollfus
- Laboratoire de Génétique Médicale, UMR_S INSERM U1112, Institut de Génétique Médicale d’Alsace (IGMA), Faculté de Médecine FMTS, Université de Strasbourg, 67000 Strasbourg, France
- Centre de Référence Pour les Affections Rares en Génétique Ophtalmologique (CARGO), Institut de Génétique Médicale d’Alsace (IGMA), Filière SENSGENE, Hôpitaux Universitaires de Strasbourg, 67091 Strasbourg, France
- Service de Génétique Médicale, Institut de Génétique Médicale d’Alsace (IGMA), Hôpitaux Universitaires de Strasbourg, 67000 Strasbourg, France
| | - Jean Muller
- Laboratoire de Génétique Médicale, UMR_S INSERM U1112, Institut de Génétique Médicale d’Alsace (IGMA), Faculté de Médecine FMTS, Université de Strasbourg, 67000 Strasbourg, France
- Laboratoires de Diagnostic Génétique, Hôpitaux Universitaires de Strasbourg, 67000 Strasbourg, France (E.N.)
- Unité Fonctionnelle de Bioinformatique Médicale Appliquée au Diagnostic (UF7363), Hôpitaux Universitaires de Strasbourg, 67000 Strasbourg, France
| |
Collapse
|
8
|
Legrand N, Salameh P, Jullien M, Chevallier P, Ferron E, David G, Devilder MC, Willem C, Gendzekhadze K, Parham P, Retière C, Gagne K. Non-Expressed Donor KIR3DL1 Alleles May Represent a Risk Factor for Relapse after T-Replete Haploidentical Hematopoietic Stem Cell Transplantation. Cancers (Basel) 2023; 15:2754. [PMID: 37345091 DOI: 10.3390/cancers15102754] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/30/2023] [Revised: 05/03/2023] [Accepted: 05/09/2023] [Indexed: 06/23/2023] Open
Abstract
KIR3DL1 alleles are expressed at different levels on the natural killer (NK) cell surface. In particular, the non-expressed KIR3DL1*004 allele appears to be common in Caucasian populations. However, the overall distribution of non-expressed KIR3DL1 alleles and their clinical relevance after T-replete haploidentical hematopoietic stem cell transplantation (hHSCT) with post-transplant cyclophosphamide remain poorly documented in European populations. In a cohort of French blood donors (N = 278), we compared the distribution of expressed and non-expressed KIR3DL1 alleles using next-generation sequencing (NGS) technology combined with multi-color flow cytometry. We confirmed the predominance of the non-expressed KIR3DL1*004 allele. Using allele-specific constructs, the phenotype and function of the uncommon KIR3DL1*019 allotype were characterized using the Jurkat T cell line and NKL transfectants. Although poorly expressed on the NK cell surface, KIR3DL1*019 is retained within NK cells, where it induces missing self-recognition of the Bw4 epitope. Transposing our in vitro observations to a cohort of hHSCT patients (N = 186) led us to observe that non-expressed KIR3DL1 HSC grafts increased the incidence of relapse in patients with myeloid diseases. Non-expressed KIR3DL1 alleles could, therefore, influence the outcome of hHSCT.
Collapse
Affiliation(s)
- Nolwenn Legrand
- Etablissement Français du Sang (EFS), F-44011 Nantes, France
- Institut National de la Santé et de la Recherche Médicale (INSERM) UMR1307, CNRS UMR 6075, Centre de Recherche en Cancérologie et Immunologie Integrée Nantes Angers (CRCI2NA), Team 12, F-44000 Nantes, France
- LabEx IGO "Immunotherapy, Graft, Oncology", F-44000 Nantes, France
| | - Perla Salameh
- Etablissement Français du Sang (EFS), F-44011 Nantes, France
- Institut National de la Santé et de la Recherche Médicale (INSERM) UMR1307, CNRS UMR 6075, Centre de Recherche en Cancérologie et Immunologie Integrée Nantes Angers (CRCI2NA), Team 12, F-44000 Nantes, France
- LabEx IGO "Immunotherapy, Graft, Oncology", F-44000 Nantes, France
| | - Maxime Jullien
- Etablissement Français du Sang (EFS), F-44011 Nantes, France
- Institut National de la Santé et de la Recherche Médicale (INSERM) UMR1307, CNRS UMR 6075, Centre de Recherche en Cancérologie et Immunologie Integrée Nantes Angers (CRCI2NA), Team 12, F-44000 Nantes, France
- LabEx IGO "Immunotherapy, Graft, Oncology", F-44000 Nantes, France
- Department of Hematology Clinic, Nantes University Hospital, F-44000 Nantes, France
| | - Patrice Chevallier
- Institut National de la Santé et de la Recherche Médicale (INSERM) UMR1307, CNRS UMR 6075, Centre de Recherche en Cancérologie et Immunologie Integrée Nantes Angers (CRCI2NA), Team 12, F-44000 Nantes, France
- LabEx IGO "Immunotherapy, Graft, Oncology", F-44000 Nantes, France
- Department of Hematology Clinic, Nantes University Hospital, F-44000 Nantes, France
| | - Enora Ferron
- Etablissement Français du Sang (EFS), F-44011 Nantes, France
- Institut National de la Santé et de la Recherche Médicale (INSERM) UMR1307, CNRS UMR 6075, Centre de Recherche en Cancérologie et Immunologie Integrée Nantes Angers (CRCI2NA), Team 12, F-44000 Nantes, France
- LabEx IGO "Immunotherapy, Graft, Oncology", F-44000 Nantes, France
| | - Gaelle David
- Etablissement Français du Sang (EFS), F-44011 Nantes, France
- Institut National de la Santé et de la Recherche Médicale (INSERM) UMR1307, CNRS UMR 6075, Centre de Recherche en Cancérologie et Immunologie Integrée Nantes Angers (CRCI2NA), Team 12, F-44000 Nantes, France
- LabEx IGO "Immunotherapy, Graft, Oncology", F-44000 Nantes, France
| | - Marie-Claire Devilder
- Institut National de la Santé et de la Recherche Médicale (INSERM) UMR1307, CNRS UMR 6075, Centre de Recherche en Cancérologie et Immunologie Integrée Nantes Angers (CRCI2NA), Team 12, F-44000 Nantes, France
- LabEx IGO "Immunotherapy, Graft, Oncology", F-44000 Nantes, France
| | - Catherine Willem
- Etablissement Français du Sang (EFS), F-44011 Nantes, France
- Institut National de la Santé et de la Recherche Médicale (INSERM) UMR1307, CNRS UMR 6075, Centre de Recherche en Cancérologie et Immunologie Integrée Nantes Angers (CRCI2NA), Team 12, F-44000 Nantes, France
- LabEx IGO "Immunotherapy, Graft, Oncology", F-44000 Nantes, France
| | - Ketevan Gendzekhadze
- Department of Hematology and HCT, HLA Laboratory, City of Hope, Medical Center, Duarte, CA 91010, USA
| | - Peter Parham
- Department of Structural Biology and Microbiology & Immunology, Stanford University School of Medicine, Stanford, CA 94305, USA
| | - Christelle Retière
- Etablissement Français du Sang (EFS), F-44011 Nantes, France
- Institut National de la Santé et de la Recherche Médicale (INSERM) UMR1307, CNRS UMR 6075, Centre de Recherche en Cancérologie et Immunologie Integrée Nantes Angers (CRCI2NA), Team 12, F-44000 Nantes, France
- LabEx IGO "Immunotherapy, Graft, Oncology", F-44000 Nantes, France
| | - Katia Gagne
- Etablissement Français du Sang (EFS), F-44011 Nantes, France
- Institut National de la Santé et de la Recherche Médicale (INSERM) UMR1307, CNRS UMR 6075, Centre de Recherche en Cancérologie et Immunologie Integrée Nantes Angers (CRCI2NA), Team 12, F-44000 Nantes, France
- LabEx IGO "Immunotherapy, Graft, Oncology", F-44000 Nantes, France
- LabEx Transplantex, Université de Strasbourg, F-67000 Strasbourg, France
| |
Collapse
|
9
|
Gouhier C, Pons-Rejraji H, Dollet S, Chaput L, Bourgne C, Berger M, Pereira B, Tchirkov A, Brugnon F. Freezing Does Not Alter Sperm Telomere Length despite Increasing DNA Oxidation and Fragmentation. Genes (Basel) 2023; 14:genes14051039. [PMID: 37239399 DOI: 10.3390/genes14051039] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/10/2023] [Revised: 04/28/2023] [Accepted: 04/30/2023] [Indexed: 05/28/2023] Open
Abstract
Correlations were reported between sperm telomere length (STL) and male fertility, sperm DNA fragmentation, and oxidation. Sperm freezing is widely used for assisted reproductive techniques, fertility preservation, and sperm donation. However, its impact on STL remains unknown. For this study, semen surplus from patients who underwent routine semen analysis were used. The impact of slow freezing on STL was analyzed by performing qPCR before and after freezing. Sperm populations with different STL were evaluated using Q-FISH. The relationship between sperm DNA oxidation, DNA fragmentation, and STL was assessed in fresh and frozen sperm samples. No significant impact of slow freezing on STL was observed, neither measured by qPCR nor Q-FISH. However, Q-FISH allowed for the distinguishing of sperm populations with different STLs within individual sperm samples. Slow freezing induced different STL distributions for some of the analyzed sperm samples, but no correlation was found between STL and sperm DNA fragmentation or oxidation. Slow freezing does not alter STL despite increasing sperm DNA oxidation and fragmentation. As STL alterations could be transmitted to offspring, the lack of impact of the slow freezing method on STL ensures the safety of this procedure.
Collapse
Affiliation(s)
- Charlène Gouhier
- CHU Clermont-Ferrand, Laboratoire AMP-CECOS, F-63003 Clermont-Ferrand, France
| | - Hanae Pons-Rejraji
- CHU Clermont-Ferrand, Laboratoire AMP-CECOS, F-63003 Clermont-Ferrand, France
- UMR 1240 INSERM, IMoST, Université Clermont Auvergne, F-63000 Clermont-Ferrand, France
| | - Sandra Dollet
- UMR 1240 INSERM, IMoST, Université Clermont Auvergne, F-63000 Clermont-Ferrand, France
| | - Laure Chaput
- CHU Clermont-Ferrand, Laboratoire AMP-CECOS, F-63003 Clermont-Ferrand, France
- UMR 1240 INSERM, IMoST, Université Clermont Auvergne, F-63000 Clermont-Ferrand, France
| | - Céline Bourgne
- CHU Clermont Ferrand, Laboratoire d'Hématologie Biologique, F-63003 Clermont-Ferrand, France
| | - Marc Berger
- CHU Clermont Ferrand, Laboratoire d'Hématologie Biologique, F-63003 Clermont-Ferrand, France
| | - Bruno Pereira
- CHU Clermont-Ferrand, DRCI-Délégation Recherche Clinique et Innovation, F-63000 Clermont-Ferrand, France
| | - Andrei Tchirkov
- CHU Clermont-Ferrand, Service de Cytogénétique Médicale, F-63003 Clermont-Ferrand, France
| | - Florence Brugnon
- CHU Clermont-Ferrand, Laboratoire AMP-CECOS, F-63003 Clermont-Ferrand, France
- UMR 1240 INSERM, IMoST, Université Clermont Auvergne, F-63000 Clermont-Ferrand, France
| |
Collapse
|
10
|
Nguyen NK, Devilder MC, Gautreau-Rolland L, Fourgeux C, Sinha D, Poschmann J, Hourmant M, Bressollette-Bodin C, Saulquin X, McIlroy D. A cluster of broadly neutralizing IgG against BK polyomavirus in a repertoire dominated by IgM. Life Sci Alliance 2023; 6:e202201567. [PMID: 36717250 PMCID: PMC9887757 DOI: 10.26508/lsa.202201567] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/20/2022] [Revised: 12/30/2022] [Accepted: 01/04/2023] [Indexed: 01/31/2023] Open
Abstract
The BK polyomavirus (BKPyV) is an opportunistic pathogen, which is only pathogenic in immunosuppressed individuals, such as kidney transplant recipients, in whom BKPyV can cause significant morbidity. To identify broadly neutralizing antibodies against this virus, we used fluorescence-labeled BKPyV virus-like particles to sort BKPyV-specific B cells from the PBMC of KTx recipients, then single-cell RNAseq to obtain paired heavy- and light-chain antibody sequences from 2,106 sorted B cells. The BKPyV-specific repertoire was highly diverse in terms of both V-gene usage and clonotype diversity and included most of the IgM B cells, including many with extensive somatic hypermutation. In two patients where sufficient data were available, IgM B cells in the BKPyV-specific dataset had significant differences in V-gene usage compared with IgG B cells from the same patient. CDR3 sequence-based clustering allowed us to identify and characterize three broadly neutralizing "41F17-like" clonotypes that were predominantly IgG, suggesting that some specific BKPyV capsid epitopes are preferentially targeted by IgG.
Collapse
Affiliation(s)
- Ngoc-Khanh Nguyen
- Nantes Universitéhttps://ror.org/05c1qsg97 , CHU Nantes, INSERM, Center for Research in Transplantation and Translational Immunology, UMR 1064, ITUN, Nantes, France
| | - Marie-Claire Devilder
- Nantes Université, Inserm UMR 1307, CNRS UMR 6075, Université d'Angers, CRCI2NA, Nantes, France
| | - Laetitia Gautreau-Rolland
- Nantes Université, Inserm UMR 1307, CNRS UMR 6075, Université d'Angers, CRCI2NA, Nantes, France
- UFR Sciences et Techniques, Nantes Université, Nantes, France
| | - Cynthia Fourgeux
- Nantes Universitéhttps://ror.org/05c1qsg97 , CHU Nantes, INSERM, Center for Research in Transplantation and Translational Immunology, UMR 1064, ITUN, Nantes, France
| | - Debajyoti Sinha
- Nantes Universitéhttps://ror.org/05c1qsg97 , CHU Nantes, INSERM, Center for Research in Transplantation and Translational Immunology, UMR 1064, ITUN, Nantes, France
| | - Jeremie Poschmann
- Nantes Universitéhttps://ror.org/05c1qsg97 , CHU Nantes, INSERM, Center for Research in Transplantation and Translational Immunology, UMR 1064, ITUN, Nantes, France
| | - Maryvonne Hourmant
- CHU Nanteshttps://ror.org/03gnr7b55 , Nantes Université, Service de Néphrologie-Immunologie clinique, Nantes, France
| | - Céline Bressollette-Bodin
- Nantes Universitéhttps://ror.org/05c1qsg97 , CHU Nantes, INSERM, Center for Research in Transplantation and Translational Immunology, UMR 1064, ITUN, Nantes, France
- CHU Nanteshttps://ror.org/03gnr7b55 , Nantes Université, Service de Virologie, Nantes, France
- UFR Médecine, Nantes Université, Nantes, France
| | - Xavier Saulquin
- Nantes Université, Inserm UMR 1307, CNRS UMR 6075, Université d'Angers, CRCI2NA, Nantes, France
- UFR Sciences et Techniques, Nantes Université, Nantes, France
| | - Dorian McIlroy
- Nantes Universitéhttps://ror.org/05c1qsg97 , CHU Nantes, INSERM, Center for Research in Transplantation and Translational Immunology, UMR 1064, ITUN, Nantes, France
- UFR Sciences et Techniques, Nantes Université, Nantes, France
| |
Collapse
|
11
|
Ferrera R, Védère M, Lo-Grasso M, Augeul L, Chouabe C, Bidaux G, Baetz D. Postconditioning by Delayed Administration of Ciclosporin A: Implication for Donation after Circulatory Death (DCD). Int J Mol Sci 2022; 23:12858. [PMID: 36361649 PMCID: PMC9657531 DOI: 10.3390/ijms232112858] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/16/2022] [Revised: 10/21/2022] [Accepted: 10/21/2022] [Indexed: 11/16/2022] Open
Abstract
Heart transplantation is facing a shortage of grafts. Donation after Circulatory Death (DCD) would constitute a new potential of available organs. In the present work, we aimed to evaluate whether Postconditioning (ischemic or with ciclosporin-A (CsA)) could reduce ischemia-reperfusion injury in a cardiac arrest model when applied at the start of reperfusion or after a delay. An isolated rat heart model was used as a model of DCD. Hearts were submitted to a cardiac arrest of 40 min of global warm ischemia (37 °C) followed by 3 h of 4 °C-cold preservation, then 60 min reperfusion. Hearts were randomly allocated into the following groups: control, ischemic postconditioning (POST, consisting of two episodes each of 30 s ischemia and 30 s reperfusion at the onset of reperfusion), and CsA group (CsA was perfused at 250 nM for 10 min at reperfusion). In respective subgroups, POST and CsA were applied after a delay of 3, 10, and 20 min. Necrosis was lower in CsA and POST versus controls (p < 0.01) whereas heart functions were improved (p < 0.01). However, while the POST lost its efficacy if delayed beyond 3 min of reperfusion, CsA treatment surprisingly showed a reduction of necrosis even if applied after a delay of 3 and 10 min of reperfusion (p < 0.01). This cardioprotection by delayed CsA application correlated with better functional recovery and higher mitochondrial respiratory index. Furthermore, calcium overload necessary to induce mitochondrial permeability transition pore (MPTP) opening was similar in all cardioprotection groups, suggesting a crucial role of MPTP in this delayed protection of DCD hearts.
Collapse
Affiliation(s)
- René Ferrera
- University of Lyon, CARMEN Laboratory, INSERM, INRAE, Université Claude Bernard Lyon 1, 69500 Lyon, France
| | - Marie Védère
- University of Lyon, CARMEN Laboratory, INSERM, INRAE, Université Claude Bernard Lyon 1, 69500 Lyon, France
| | - Megane Lo-Grasso
- University of Lyon, CARMEN Laboratory, INSERM, INRAE, Université Claude Bernard Lyon 1, 69500 Lyon, France
| | - Lionel Augeul
- University of Lyon, CARMEN Laboratory, INSERM, INRAE, Université Claude Bernard Lyon 1, 69500 Lyon, France
| | - Christophe Chouabe
- University of Lyon, CARMEN Laboratory, INSERM, INRAE, Université Claude Bernard Lyon 1, 69500 Lyon, France
| | - Gabriel Bidaux
- University of Lyon, CARMEN Laboratory, INSERM, INRAE, Université Claude Bernard Lyon 1, 69500 Lyon, France
| | - Delphine Baetz
- University of Lyon, CARMEN Laboratory, INSERM, INRAE, Université Claude Bernard Lyon 1, 69500 Lyon, France
| |
Collapse
|
12
|
Ghieh F, Barbotin AL, Swierkowski-Blanchard N, Leroy C, Fortemps J, Gerault C, Hue C, Mambu Mambueni H, Jaillard S, Albert M, Bailly M, Izard V, Molina-Gomes D, Marcelli F, Prasivoravong J, Serazin V, Dieudonne MN, Delcroix M, Garchon HJ, Louboutin A, Mandon-Pepin B, Ferlicot S, Vialard F. OUP accepted manuscript. Hum Reprod 2022; 37:1334-1350. [PMID: 35413094 PMCID: PMC9156845 DOI: 10.1093/humrep/deac057] [Citation(s) in RCA: 4] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/28/2021] [Revised: 03/07/2022] [Indexed: 11/13/2022] Open
Affiliation(s)
- F Ghieh
- Université Paris-Saclay, UVSQ, INRAE, BREED, Jouy-en-Josas, France
- École Nationale Vétérinaire d’Alfort, BREED, Maisons-Alfort, France
| | - A L Barbotin
- Institut de Biologie de la Reproduction-Spermiologie-CECOS, Hôpital Jeanne de Flandre, Centre Hospitalier et Universitaire, Lille, France
| | - N Swierkowski-Blanchard
- Université Paris-Saclay, UVSQ, INRAE, BREED, Jouy-en-Josas, France
- École Nationale Vétérinaire d’Alfort, BREED, Maisons-Alfort, France
- Département de Gynécologie Obstétrique, CHI de Poissy/Saint-Germain-en-Laye, Poissy, France
| | - C Leroy
- Institut de Biologie de la Reproduction-Spermiologie-CECOS, Hôpital Jeanne de Flandre, Centre Hospitalier et Universitaire, Lille, France
| | - J Fortemps
- Service d’Anatomie Pathologique, CHI de Poissy/Saint-Germain-en-Laye, Saint-Germain-en-Laye, France
| | - C Gerault
- Département de Génétique, Laboratoire de Biologie Médicale, CHI de Poissy/Saint-Germain-en-Laye, Poissy, France
| | - C Hue
- Department of Biotechnology and Health, UVSQ, Université Paris-Saclay, Inserm UMR 1173, Montigny-le-Bretonneux, France
| | - H Mambu Mambueni
- Department of Biotechnology and Health, UVSQ, Université Paris-Saclay, Inserm UMR 1173, Montigny-le-Bretonneux, France
| | - S Jaillard
- Service de Cytogénétique, CHU Rennes, Rennes, France
- INSERM, EHESP, IRSET—UMR_S 1085, Université Rennes 1, Rennes, France
| | - M Albert
- Université Paris-Saclay, UVSQ, INRAE, BREED, Jouy-en-Josas, France
- École Nationale Vétérinaire d’Alfort, BREED, Maisons-Alfort, France
| | - M Bailly
- Département de Gynécologie Obstétrique, CHI de Poissy/Saint-Germain-en-Laye, Poissy, France
| | - V Izard
- Service d’Urologie, AP-HP, Université Paris-Saclay, Hôpital de Bicêtre, Le Kremlin-Bicêtre, France
| | - D Molina-Gomes
- Département de Génétique, Laboratoire de Biologie Médicale, CHI de Poissy/Saint-Germain-en-Laye, Poissy, France
| | - F Marcelli
- Institut de Biologie de la Reproduction-Spermiologie-CECOS, Hôpital Jeanne de Flandre, Centre Hospitalier et Universitaire, Lille, France
| | - J Prasivoravong
- Institut de Biologie de la Reproduction-Spermiologie-CECOS, Hôpital Jeanne de Flandre, Centre Hospitalier et Universitaire, Lille, France
| | - V Serazin
- Université Paris-Saclay, UVSQ, INRAE, BREED, Jouy-en-Josas, France
- École Nationale Vétérinaire d’Alfort, BREED, Maisons-Alfort, France
- Département de Génétique, Laboratoire de Biologie Médicale, CHI de Poissy/Saint-Germain-en-Laye, Poissy, France
| | - M N Dieudonne
- Université Paris-Saclay, UVSQ, INRAE, BREED, Jouy-en-Josas, France
- École Nationale Vétérinaire d’Alfort, BREED, Maisons-Alfort, France
| | - M Delcroix
- Département de Génétique, Laboratoire de Biologie Médicale, CHI de Poissy/Saint-Germain-en-Laye, Poissy, France
| | - H J Garchon
- Department of Biotechnology and Health, UVSQ, Université Paris-Saclay, Inserm UMR 1173, Montigny-le-Bretonneux, France
| | - A Louboutin
- Service d’Anatomie Pathologique, CHI de Poissy/Saint-Germain-en-Laye, Saint-Germain-en-Laye, France
| | - B Mandon-Pepin
- Université Paris-Saclay, UVSQ, INRAE, BREED, Jouy-en-Josas, France
- École Nationale Vétérinaire d’Alfort, BREED, Maisons-Alfort, France
| | - S Ferlicot
- Service d’Anatomie Pathologique, AP-HP, Université Paris-Saclay, Hôpital de Bicêtre, Le Kremlin-Bicêtre, France
| | - F Vialard
- Correspondence address. Tel: +33-139-274-700; E-mail:
| |
Collapse
|
13
|
Benoit A, Grynberg M, Morello R, Sermondade N, Grandazzi G, Moutel G. Does a web-based decision aid improve informed choice for fertility preservation in women with breast cancer (DECISIF)? Study protocol for a randomised controlled trial. BMJ Open 2020; 10:e031739. [PMID: 32047010 PMCID: PMC7044978 DOI: 10.1136/bmjopen-2019-031739] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/16/2019] [Revised: 12/04/2019] [Accepted: 12/05/2019] [Indexed: 01/29/2023] Open
Abstract
INTRODUCTION Chemotherapy may cause infertility in young survivors of breast cancer. Various fertility preservation techniques increase the likelihood of survivors becoming genetic mothers. Disclosure of cancer diagnosis may impact decision making about fertility preservation. This protocol will develop and test the effectiveness of a web-based decision aid for helping women with breast cancer to make well-informed choices about fertility preservation. METHODS AND ANALYSIS This study will be conducted in three phases using mixed methods. In phase I, the aim is to develop a web-based patient decision aid (PDA) in French with a steering committee and using a focus group of five women already treated for breast cancer. In phase II, the face validity of the decision aid will be assessed using questionnaires. In phase III, the PDA will be assessed by a two-arm randomised controlled trial. This will involve a quantitative evaluation of the PDA in clinical practice comparing the quality of the decision-making process between usual care and the PDA. The primary outcome will be informed choice and its components. The secondary outcomes will be decisional conflict and anxiety. Data will be collected during and after an oncofertility consultation. Phase III is underway. Since September 2018, 52 participants have been enrolled in the study and have completed the survey. We expect to have results by February 2020 for a total of 186 patients. ETHICS AND DISSEMINATION This study protocol was approved by the Ouest V Research Ethics Board. Results will be spread through peer-reviewed publications, and reported at suitable meetings. TRIAL REGISTRATION NUMBER The ClinicalTrials.gov registry .(NCT03591848).
Collapse
Affiliation(s)
- Alexandra Benoit
- UNICAEN, Inserm U1086, ANTICIPE, Normandie Université, Caen, France
- Department of Reproductive Medicine and Fertility Preservation, Hôpital Antoine-Béclère, Clamart, France
| | - Michael Grynberg
- Department of Reproductive Medicine and Fertility Preservation, Hôpital Antoine-Béclère, Clamart, France
- U1133, Université Paris Diderot, Paris, France
| | - Rémy Morello
- UNICAEN, Inserm U1086, ANTICIPE, Normandie Universite, Caen, France
- Biostatistics and Clinical Research Unit, CHU Caen, Caen, France
| | - Nathalie Sermondade
- Department of Cytogenetic and Reproductive Biology, Hôpital Jean Verdier, Bondy, France
| | - Guillaume Grandazzi
- UNICAEN, Inserm U1086, ANTICIPE, Normandie Universite, Caen, France
- Espace Régional de Réflexion éthique, CHU Caen, Caen, France
| | - Grégoire Moutel
- UNICAEN, Inserm U1086, ANTICIPE, Normandie Universite, Caen, France
- Espace Régional de Réflexion éthique, CHU Caen, Caen, France
| |
Collapse
|
14
|
Durand AC, Jouve E, Delarozière JC, Boucekine M, Izaaryene G, Crémades A, Mazoué F, Devictor B, Kakar A, Sambuc R, Brunet P, Gentile S. End-stage renal disease treated in Provence-Alpes Côte d'Azur: 12-years follow-up and forecast to the year 2030. BMC Nephrol 2018; 19:141. [PMID: 29907091 PMCID: PMC6003073 DOI: 10.1186/s12882-018-0929-y] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/31/2017] [Accepted: 05/24/2018] [Indexed: 11/10/2022] Open
Abstract
BACKGROUND This study describes the time trend of renal replacement therapy for end-stage renal disease (ESRD) in the Provence-Alpes Côte d'Azur region (PACA) between 2004 and 2015, and forecasts up to 2030. METHODS A longitudinal study was conducted on all ESRD patients treated in PACA and recorded in the French Renal Epidemiology and Information Network (REIN) during this period. Time trends and forecasts to 2030 were analyzed using Poisson regression models. RESULTS Since 2004, the number of new patients has steadily increased by 3.4% per year (95% CI, 2.8-3.9, p < 0.001) and the number of patients receiving RRT has increased by 3.7% per year (RR 1.037, 95% CI: 1.034-1.039, p < 0.001). If these trends continue, the PACA region will be face with 7371 patients on dialysis and 3891 with a functional renal transplant who will need to be managed in 2030. The two most significant growth rates were the percentage of obese people (RR 1.140, 95% CI: 1.131-1.149, p < 0.001) and those with diabetes (RR 1.070, 95% CI; 1.064-1.075, p < 0.001). CONCLUSION This study highlights the increase in the number of ESRD patients over 12 years, with no prospect of stabilization. These findings allow us to anticipate the quality and quantity of care offered and to propose more preventive measures to combat obesity and diabetes.
Collapse
Affiliation(s)
- Anne-Claire Durand
- Aix-Marseille University, EA 3279, Public Health, Chronic Diseases and Quality of Life research Unit, 27 Boulevard Jean Moulin, 13385 Marseille cedex 5, France
- Cellule d’appui épidémiologique, registre REIN Provence-Alpes Côtes d’Azur, Hôpital de La Conception, Assistance Publique - Hôpitaux de Marseille, Marseille, France
| | - Elisabeth Jouve
- Service d’Evaluation Médicale, Hôpital de La Conception, Assistance Publique - Hôpitaux de Marseille, Marseille, France
| | - Jean-Christophe Delarozière
- Aix-Marseille University, EA 3279, Public Health, Chronic Diseases and Quality of Life research Unit, 27 Boulevard Jean Moulin, 13385 Marseille cedex 5, France
- Cellule d’appui épidémiologique, registre REIN Provence-Alpes Côtes d’Azur, Hôpital de La Conception, Assistance Publique - Hôpitaux de Marseille, Marseille, France
| | - Mohamed Boucekine
- Aix-Marseille University, EA 3279, Public Health, Chronic Diseases and Quality of Life research Unit, 27 Boulevard Jean Moulin, 13385 Marseille cedex 5, France
| | - Ghizlane Izaaryene
- Aix-Marseille University, EA 3279, Public Health, Chronic Diseases and Quality of Life research Unit, 27 Boulevard Jean Moulin, 13385 Marseille cedex 5, France
- Cellule d’appui épidémiologique, registre REIN Provence-Alpes Côtes d’Azur, Hôpital de La Conception, Assistance Publique - Hôpitaux de Marseille, Marseille, France
| | - Adeline Crémades
- Aix-Marseille University, EA 3279, Public Health, Chronic Diseases and Quality of Life research Unit, 27 Boulevard Jean Moulin, 13385 Marseille cedex 5, France
- Cellule d’appui épidémiologique, registre REIN Provence-Alpes Côtes d’Azur, Hôpital de La Conception, Assistance Publique - Hôpitaux de Marseille, Marseille, France
| | - Franck Mazoué
- Aix-Marseille University, EA 3279, Public Health, Chronic Diseases and Quality of Life research Unit, 27 Boulevard Jean Moulin, 13385 Marseille cedex 5, France
- Cellule d’appui épidémiologique, registre REIN Provence-Alpes Côtes d’Azur, Hôpital de La Conception, Assistance Publique - Hôpitaux de Marseille, Marseille, France
| | - Bénédicte Devictor
- Aix-Marseille University, EA 3279, Public Health, Chronic Diseases and Quality of Life research Unit, 27 Boulevard Jean Moulin, 13385 Marseille cedex 5, France
| | - Asmatullah Kakar
- Aix-Marseille University, EA 3279, Public Health, Chronic Diseases and Quality of Life research Unit, 27 Boulevard Jean Moulin, 13385 Marseille cedex 5, France
| | - Roland Sambuc
- Aix-Marseille University, EA 3279, Public Health, Chronic Diseases and Quality of Life research Unit, 27 Boulevard Jean Moulin, 13385 Marseille cedex 5, France
- Cellule d’appui épidémiologique, registre REIN Provence-Alpes Côtes d’Azur, Hôpital de La Conception, Assistance Publique - Hôpitaux de Marseille, Marseille, France
| | - Philippe Brunet
- Cellule d’appui épidémiologique, registre REIN Provence-Alpes Côtes d’Azur, Hôpital de La Conception, Assistance Publique - Hôpitaux de Marseille, Marseille, France
- Department of nephrology and renal transplantation, Hôpital de La Conception, Assistance Publique - Hôpitaux de Marseille, Marseille, France
| | - Stéphanie Gentile
- Aix-Marseille University, EA 3279, Public Health, Chronic Diseases and Quality of Life research Unit, 27 Boulevard Jean Moulin, 13385 Marseille cedex 5, France
- Cellule d’appui épidémiologique, registre REIN Provence-Alpes Côtes d’Azur, Hôpital de La Conception, Assistance Publique - Hôpitaux de Marseille, Marseille, France
- Service d’Evaluation Médicale, Hôpital de La Conception, Assistance Publique - Hôpitaux de Marseille, Marseille, France
| |
Collapse
|
15
|
Jouand N, Bressollette-Bodin C, Gérard N, Giral M, Guérif P, Rodallec A, Oger R, Parrot T, Allard M, Cesbron-Gautier A, Gervois N, Charreau B. HCMV triggers frequent and persistent UL40-specific unconventional HLA-E-restricted CD8 T-cell responses with potential autologous and allogeneic peptide recognition. PLoS Pathog 2018; 14:e1007041. [PMID: 29709038 PMCID: PMC5945056 DOI: 10.1371/journal.ppat.1007041] [Citation(s) in RCA: 22] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/06/2017] [Revised: 05/10/2018] [Accepted: 04/17/2018] [Indexed: 01/08/2023] Open
Abstract
Immune response against human cytomegalovirus (HCMV) includes a set of persistent cytotoxic NK and CD8 T cells devoted to eliminate infected cells and to prevent reactivation. CD8 T cells against HCMV antigens (pp65, IE1) presented by HLA class-I molecules are well characterized and they associate with efficient virus control. HLA-E-restricted CD8 T cells targeting HCMV UL40 signal peptides (HLA-EUL40) have recently emerged as a non-conventional T-cell response also observed in some hosts. The occurrence, specificity and features of HLA-EUL40 CD8 T-cell responses remain mostly unknown. Here, we detected and quantified these responses in blood samples from healthy blood donors (n = 25) and kidney transplant recipients (n = 121) and we investigated the biological determinants involved in their occurrence. Longitudinal and phenotype ex vivo analyses were performed in comparison to HLA-A*02/pp65-specific CD8 T cells. Using a set of 11 HLA-E/UL40 peptide tetramers we demonstrated the presence of HLA-EUL40 CD8 αβT cells in up to 32% of seropositive HCMV+ hosts that may represent up to 38% of total circulating CD8 T-cells at a time point suggesting a strong expansion post-infection. Host's HLA-A*02 allele, HLA-E *01:01/*01:03 genotype and sequence of the UL40 peptide from the infecting strain are major factors affecting the incidence of HLA-EUL40 CD8 T cells. These cells are effector memory CD8 (CD45RAhighROlow, CCR7-, CD27-, CD28-) characterized by a low level of PD-1 expression. HLA-EUL40 responses appear early post-infection and display a broad, unbiased, Vβ repertoire. Although induced in HCMV strain-dependent, UL4015-23-specific manner, HLA-EUL40 CD8 T cells are reactive toward a broader set of nonapeptides varying in 1-3 residues including most HLA-I signal peptides. Thus, HCMV induces strong and life-long lasting HLA-EUL40 CD8 T cells with potential allogeneic or/and autologous reactivity that take place selectively in at least a third of infections according to virus strain and host HLA concordance.
Collapse
Affiliation(s)
- Nicolas Jouand
- Centre de Recherche en Transplantation et Immunologie (CRTI), UMR1064, INSERM, Université de Nantes, Nantes, France
- Institut de Transplantation Urologie Néphrologie (ITUN), CHU Nantes, Nantes, France
- CRCINA, UMR1232, INSERM, Université d’Angers, Université de Nantes, Nantes, France
- LabEx Immunology-Graft-Oncology (IGO), Nantes, France
| | - Céline Bressollette-Bodin
- Centre de Recherche en Transplantation et Immunologie (CRTI), UMR1064, INSERM, Université de Nantes, Nantes, France
- Laboratoire de Virologie, CHU Nantes, Nantes, France
| | - Nathalie Gérard
- Centre de Recherche en Transplantation et Immunologie (CRTI), UMR1064, INSERM, Université de Nantes, Nantes, France
- Institut de Transplantation Urologie Néphrologie (ITUN), CHU Nantes, Nantes, France
| | - Magali Giral
- Centre de Recherche en Transplantation et Immunologie (CRTI), UMR1064, INSERM, Université de Nantes, Nantes, France
- Institut de Transplantation Urologie Néphrologie (ITUN), CHU Nantes, Nantes, France
| | - Pierrick Guérif
- Institut de Transplantation Urologie Néphrologie (ITUN), CHU Nantes, Nantes, France
| | | | - Romain Oger
- CRCINA, UMR1232, INSERM, Université d’Angers, Université de Nantes, Nantes, France
| | - Tiphaine Parrot
- CRCINA, UMR1232, INSERM, Université d’Angers, Université de Nantes, Nantes, France
| | - Mathilde Allard
- CRCINA, UMR1232, INSERM, Université d’Angers, Université de Nantes, Nantes, France
| | - Anne Cesbron-Gautier
- Etablissement Français du Sang (EFS), Région des Pays de la Loire, Nantes, France
| | - Nadine Gervois
- CRCINA, UMR1232, INSERM, Université d’Angers, Université de Nantes, Nantes, France
- LabEx Immunology-Graft-Oncology (IGO), Nantes, France
| | - Béatrice Charreau
- Centre de Recherche en Transplantation et Immunologie (CRTI), UMR1064, INSERM, Université de Nantes, Nantes, France
- Institut de Transplantation Urologie Néphrologie (ITUN), CHU Nantes, Nantes, France
- LabEx Immunology-Graft-Oncology (IGO), Nantes, France
- Institut Hospitalo-Universitaire European Center for Science in Transplantation and Immunology, Nantes, France
| |
Collapse
|
16
|
Alencar de Pinho N, Coscas R, Metzger M, Labeeuw M, Ayav C, Jacquelinet C, Massy ZA, Stengel B. Predictors of nonfunctional arteriovenous access at hemodialysis initiation and timing of access creation: A registry-based study. PLoS One 2017; 12:e0181254. [PMID: 28749967 PMCID: PMC5531527 DOI: 10.1371/journal.pone.0181254] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/26/2016] [Accepted: 06/28/2017] [Indexed: 12/21/2022] Open
Abstract
Determinants of nonfunctional arteriovenous (AV) access, including timing of AV access creation, have not been sufficiently described. We studied 29 945 patients who had predialysis AV access placement and were included in the French REIN registry from 2005 through 2013. AV access was considered nonfunctional when dialysis began with a catheter. We estimated crude and adjusted odds ratio (OR) with 95% confidence intervals (CI) of nonfunctional versus functional AV access associated with case-mix, facility characteristics, and timing of AV access creation. Analyses were stratified by dialysis start condition (planned or as an emergency) and comorbidity profile. Overall, 18% patients had nonfunctional AV access at hemodialysis initiation. In the group with planned dialysis start, female gender (OR 1.43, 95% CI 1.32–1.56), diabetes (OR 1.28, 95% CI 1.15–1.44), and a higher number of cardiovascular comorbidities (OR 1.27, 95% CI 1.09–1.49, and 1.31, 1.05–1.64, for 3 and >3 cardiovascular comorbidities versus none, respectively) were independent predictors of nonfunctional AV access. A higher percentage of AV access creation at the region level was associated with a lower rate of nonfunctional AV access (OR 0.98, 95% CI 0.98–0.99 per 1% increase). The odds of nonfunctional AV access decreased as time from creation to hemodialysis initiation increased up to 3 months in nondiabetic patients with fewer than 2 cardiovascular comorbidities and 6 months in patients with diabetes or 2 or more such comorbidities. In conclusion, both patient characteristics and clinical practices may play a role in successful AV access use at hemodialysis initiation. Adjusting the timing of AV access creation to patients’ comorbidity profiles may improve functional AV access rates.
Collapse
Affiliation(s)
- Natalia Alencar de Pinho
- Renal and Cardiovascular Epidemiology Team, CESP, INSERM U1018, Paris-Sud Univ, UVSQ, Paris Saclay University,Villejuif, France
- * E-mail:
| | - Raphael Coscas
- Renal and Cardiovascular Epidemiology Team, CESP, INSERM U1018, Paris-Sud Univ, UVSQ, Paris Saclay University,Villejuif, France
- Division of Vascular Surgery, Ambroise Paré University Hospital, AP-HP, Boulogne-Billancourt, France
| | - Marie Metzger
- Renal and Cardiovascular Epidemiology Team, CESP, INSERM U1018, Paris-Sud Univ, UVSQ, Paris Saclay University,Villejuif, France
| | | | - Carole Ayav
- Epidémiologie et Evaluations Cliniques, Pôle S2R, CHRU Nancy, Nancy, France
- CIC-1433 Epidémiologie Clinique, Inserm, Nancy, France
| | | | - Ziad A. Massy
- Renal and Cardiovascular Epidemiology Team, CESP, INSERM U1018, Paris-Sud Univ, UVSQ, Paris Saclay University,Villejuif, France
- Division of Nephrology, Ambroise Paré University Hospital, AP-HP, Boulogne-Billancourt, France
| | - Bénédicte Stengel
- Renal and Cardiovascular Epidemiology Team, CESP, INSERM U1018, Paris-Sud Univ, UVSQ, Paris Saclay University,Villejuif, France
| |
Collapse
|
17
|
Rochemont DR, Meddeb M, Roura R, Couchoud C, Nacher M, Basurko C. End stage renal disease in French Guiana (data from R.E.I.N registry): South American or French? BMC Nephrol 2017; 18:207. [PMID: 28666409 PMCID: PMC5493068 DOI: 10.1186/s12882-017-0614-6] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/17/2016] [Accepted: 06/08/2017] [Indexed: 12/20/2022] Open
Abstract
BACKGROUND End-Stage renal disease (ESRD) causes considerable morbidity and mortality, and significantly alters patients' quality of life. There are very few published data on this problem in the French Overseas territories. The development of a registry on end stage renal disease in French Guiana in 2011 allowed to describe the magnitude of this problem in the region for the first time. METHODS Using data from the French Renal Epidemiology and Information Network registry (R.E.I.N). Descriptive statistics on quantitative and qualitative variables in the registry were performed on prevalent cases and incident cases in 2011, 2012 and 2013. RESULTS French Guiana has one of the highest ESRD prevalence and incidence in France. The two main causes of ESRD were hypertensive and diabetic nephropathies. The French Guianese population had a different demographic profile (younger, more women, more migrants) than in mainland France. Most patients had at least one comorbidity, predominantly (95.3%) hypertension. In French Guiana dialysis was initiated in emergency for 71.3% of patients versus 33% in France (p < 0.001). CONCLUSION These first results give important public health information: i) End stage renal disease has a very high prevalence relative to mainland France ii) Patients have a different demographic profile and enter care late in the course of their renal disease. These data are closer to what is observed in the Caribbean or in Latin America than in Mainland France.
Collapse
Affiliation(s)
- Dévi Rita Rochemont
- Centre d’Investigation Clinique Epidémiologie Clinique Antilles Guyane CIC INSERM 1424, Centre hospitalier Andrée Rosemon, Rue des flamboyants BP 6006, 97306 Cayenne, French Guiana
| | - Mohamed Meddeb
- KAPA santé, Clinique Véronique, 1453 rte Baduel, 97300 Cayenne, French Guiana
| | - Raoul Roura
- Association Traitement de l’Insuffisance Rénale en Guyane (ATIRG), Centre hospitalier Andrée Rosemon, 1361 rte Baduel, 97300 Cayenne, French Guiana
| | - Cécile Couchoud
- Biomedecine Agency, La plaine-Saint Denis France, 1 avenue du Stade de, 93212 Saint-Denis La Plaine, France
| | - Mathieu Nacher
- Centre d’Investigation Clinique Epidémiologie Clinique Antilles Guyane CIC INSERM 1424, Centre hospitalier Andrée Rosemon, Rue des flamboyants BP 6006, 97306 Cayenne, French Guiana
- EA3593, UFR Médecine - Université des Antilles et de la Guyane, Cayenne, French Guiana
| | - Célia Basurko
- Centre d’Investigation Clinique Epidémiologie Clinique Antilles Guyane CIC INSERM 1424, Centre hospitalier Andrée Rosemon, Rue des flamboyants BP 6006, 97306 Cayenne, French Guiana
- EA3593, UFR Médecine - Université des Antilles et de la Guyane, Cayenne, French Guiana
| |
Collapse
|